OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Thrombosis and Thrombolysis is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database	54
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	39
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection	31
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia	31
Management of bone marrow biopsy related bleeding risks: a retrospective observational study	29
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery	29
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors	25
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians	24
Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status	23
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate	22
Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic	21
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry	21
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone	20
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series	18
Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals	18
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison	17
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy	17
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes	16
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding	16
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality	15
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	14
Thrombosis in VEXAS syndrome	14
Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies	14
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome	13
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum	13

Effectiveness and safety of the direct oral anticoagulants in non-triple positive antiphospholipid syndrome without prior arterial thromboembolism	13
Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes	13
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri	13
Forensic autopsy-confirmed thrombosis-related deaths: the danger in the bones	12
Metformin therapy in COVID-19: inhibition of NETosis	12
Popliteal cysts are not a risk factor for lower extremity deep vein thrombosis	12
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy	11
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis	11
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction	10
Endothelial progenitor cells overexpressing platelet derived growth factor-D facilitate deep vein thrombosis resolution	10
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study	9
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature	9
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients	9
Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall	9
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	9
A comprehensive review of vascular complications in COVID-19	9
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid	9
Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves	9
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia	9
The safety and efficacy of systemic versus catheter-based therapies: application of a prognostic model by a pulmonary embolism response team	8
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors	8
Time to consider neuroinflammation as a booster effect of cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia?	8
Juvenile patients with the homozygous MTHFR C677T genotype develop ischemic stroke 5 years earlier than wild type	8
Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism	8
SARS-CoV-2 antibody research in patients with unprovoked pulmonary embolism in COVID-19 pandemic period	8
Subclinical leaflet thrombosis after transcatheter aortic valve replacement and anticoagulant treatment: lights and shadows	8
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States	8
Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation	8
Intravenous thrombolysis and endovascular thrombectomy for acute ischaemic stroke in patients with Moyamoya disease - a systematic review and meta-summary of case reports	7
Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes	7
A survey of internists’ recommendations for aspirin in older adults and barriers to evidence-based use	7
Thromboembolic events following mRNA vaccines for COVID 19: a case series	7
Correction to: Cardiomyocyte microvesicles: proinflammatory mediators after myocardial ischemia?	7
Activated clotting time in inpatient diagnostic and interventional settings	7
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome	7
Barriers and motivators to national board certification as a certified anticoagulation care provider	7
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	6
Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells	6
Immature platelets in patients with Covid-19: association with disease severity	6
Recurrent hematuria and painful necrotic purpura induced by acquired Protein S deficiency associated with monoclonal immunoglobulin	6
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism	6
Incremental cost of venous thromboembolism in trauma patients with contraindications to prophylactic anticoagulation: a prospective economic study	6
Contemporary use of ventilation-perfusion imaging for pulmonary embolism diagnosis	6
Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation pati	6
Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012)	6
Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity	5
Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series	5
Association of acidosis with coagulopathy and transfusion requirements in liver transplantation	5
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry	5
Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes	5

REPLY to “Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	5
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study	5
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study—Reply to comment from Muzaffar et al.	5
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS	5
Evaluation of heparin infusion rates in patients with intravenous drug misuse	5
Answer to “REPLY to Association between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	5
Acute coronary syndrome in patients with hemophilia: a delicate balancing act	5